Open AccessAn overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay
Author(s) -
Esmail Jafari,
Hojjat Ahmadzadehfar,
Habibollah Dadgar,
Majid Assadi
Publication year - 2020
Publication title -
world journal of nuclear medicine
Language(s) - English
Resource type - Journals
eISSN - 1607-3312
pISSN - 1450-1147
DOI - 10.4103/wjnm.wjnm_78_19
Subject(s) - prostate cancer , medicine , glutamate carboxypeptidase ii , prostate , positron emission tomography , cancer research , scintigraphy , cancer , molecular imaging , antigen , pathology , nuclear medicine , immunology , in vivo , microbiology and biotechnology , biology
Prostate-specific membrane antigen (PSMA) is a Type II transmembrane glycoprotein which is extremely overexpressed in prostate cancer epithelial cells. Recently, PSMA-targeted small molecule labeled with 68Ga and 99mTc allowed precise molecular imaging of prostate cancer and PSMA-targeted small molecule labeled with 177Lu leads to the development of radionuclide-targeted therapy of prostate cancer. Despite its name, it has been shown that PSMA has been expressed in several malignancies which can be due to significant neovascularization. Present pictorial assay reports the nonspecific tracer uptake in some malignancies during 68Ga-PSMA positron-emission tomography/computed tomography imaging and 99mTc-PSMA scintigraphy.